ICAM1 and neutropenia: The authors also reported improved neurological outcome for VAP-1 inhibition and neutropenia.99 Regarding ICAM-1, Atangana et al. observed a significant reduction in neutrophil-endothelial interactions (rolling and adhering neutrophils) after SAH in ICAM-1 knockout mice and PSGL-1 knockout mice (PSGL-1 is a leukocyte receptor that interacts with ICAM-1).